Georgia A. McCann

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg et al. · JAMA Oncology · 2019 · 413 citations · Full text

HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer

Kellie S. Rath, Shan K. Naidu, Pushpa Lata et al. · Cancer Research · 2014 · 97 citations

Chemoprevention Strategy, Gynecology, Pharmacotherapy +20

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.

Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg et al. · Journal of Clinical Oncology · 2018 · 77 citations

Breast Oncology, Oncology, Immunology +15

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

David M. O’Malley, Debra L. Richardson, Patrick S. Rheaume et al. · Gynecologic Oncology · 2011 · 51 citations

Progression-free Survival, Medicine, Cancer Management +6

The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer

Georgia A. McCann, Susanne Taege, Christina Boutsicaris et al. · Gynecologic Oncology · 2012 · 48 citations · Full text

Gynecologic Surgery, Surgical Oncology, Cervical Cancer Management +12